Sign in Subscribe
COVID-19

COVID-19 Vaccine Response in Pediatric Patients with Inflammatory Bowel Disease

Strategic Insights

— 1 min read

Research has been conducted to evaluate the effectiveness of the BNT162b2 SARS-CoV-2 vaccine in pediatric patients with inflammatory bowel disease (IBD). The study compared the postvaccination immunity response in patients with IBD to that of healthy controls. The findings revealed that patients with IBD produced higher levels of postvaccination anti-spike S2 antibodies than controls. However, this did not translate to a significant increase in overall postvaccination immunity. Furthermore, previous SARS-CoV-2 infection was associated with higher production of postvaccination antibodies, while anti-tumor necrosis factor treatment was linked to lower production.

Key Takeaways:

  • The BNT162b2 SARS-CoV-2 vaccine elicited a strong immune response in pediatric patients with IBD, as evidenced by higher levels of anti-spike S2 antibodies.
  • Patients with IBD produced higher levels of anti-spike S2 antibodies than controls, but this did not result in significantly higher postvaccination immunity.
  • Previous SARS-CoV-2 infection was associated with higher production of postvaccination antibodies, while anti-tumor necrosis factor treatment was linked to lower production.
  • Vaccination side effects were reported by 43% of patients, with most effects being mild.
  • 46% of patients with positive anti-nucleocapsid IgG had a history of SARS-CoV-2 infection.

Statistics:

  • 139 pediatric patients with IBD participated in the study.
  • The median age of patients with IBD was 16.3 years.
  • The median time from vaccination was 61 days.
  • 63% of patients with IBD developed positive anti-spike S2 IgG, compared to 21% of controls.
  • The titer of anti-spike S2 IgG was higher in patients with IBD, with a median level of 485 IU/mL.

Sources:

  • Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition, 2022;76(2).
  • Charles University and University Hospital Motol, Prague, Czech Republic.
  • Ivana Copova, Dept. of Paediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Jiri Bronsky, Marianna Durilova, Denis Kazeka, Michal Kubat, Tereza Lerchova, Eva Vlckova, Katarina Mitrova, Michal Rataj, Adam Klocperk, Anna Sediva, and Ondrej Hradsky.

Read more